NRBO News and Press, NeuroBo Pharmaceuticals Inc.

2024-07-30 08:51:16 ET More on NeuroBo Pharmaceuticals NeuroBo Pharma prices private placement and direct offering to raise up to $70M NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals ...

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...

2024-06-24 14:31:56 ET More on NeuroBo Pharmaceuticals NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial informatio...

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in...

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models PR Newswire DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

2024-05-22 10:01:06 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone PR Newswire Data Will be Presented in Two Posters at the EASL Congress 20...